Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**N-alpha-methylhistamine** is a synthetic small molecule structurally related to histamine. It acts as a **potent agonist at histamine H3, H4, and H2 receptors**. Specifically, it has been used as a research tool and discovery agent for studying histaminergic signaling and is known to stimulate cAMP production through H2 receptor activation. NAMH has been investigated in the context of gastric mucosa, particularly in Helicobacter pylori infection, where its production is upregulated. Its agonist actions at H3 and H4 receptors are of primary interest in neuropharmacology and immunology[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-alpha-methylhistamine.